The results of four randomized, double-masked, vehicle-controlled trials showed KPI-121 0.25% is safe and well tolerated with no unexpected treatment-related adverse events in patients with dry eye disease, according to a study.
“The clinical development program for KPI-121 0.25%, which will be marketed as Eysuvis if approved, is the largest to date for a dry eye product. In over 2,800 patients across the four trials, KPI-121 0.25% administered up to 28 days appeared safe and well tolerated with no unexpected adverse events,” Kim Brazzell, PhD, chief medical officer for Kala
Uncategorized